Published in Proc Natl Acad Sci U S A on October 02, 2006
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res (2007) 37.31
Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer (2009) 5.12
TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol (2010) 4.92
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci U S A (2008) 2.30
The MORPHEUS protein crystallization screen. J Appl Crystallogr (2009) 1.87
mCSM: predicting the effects of mutations in proteins using graph-based signatures. Bioinformatics (2013) 1.69
The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol (2010) 1.64
p53-based cancer therapy. Cold Spring Harb Perspect Biol (2010) 1.62
Halogen-enriched fragment libraries as leads for drug rescue of mutant p53. J Am Chem Soc (2012) 1.50
Structural consequences of disease-causing mutations in the ATRX-DNMT3-DNMT3L (ADD) domain of the chromatin-associated protein ATRX. Proc Natl Acad Sci U S A (2007) 1.45
Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res (2013) 1.24
Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition. Proc Natl Acad Sci U S A (2012) 1.21
Rapid profiling of disease alleles using a tunable reporter of protein misfolding. Genetics (2012) 1.20
Single-Molecule characterization of oligomerization kinetics and equilibria of the tumor suppressor p53. Nucleic Acids Res (2010) 1.20
Using halogen bonds to address the protein backbone: a systematic evaluation. J Comput Aided Mol Des (2012) 1.15
Rett syndrome-causing mutations in human MeCP2 result in diverse structural changes that impact folding and DNA interactions. J Biol Chem (2008) 1.12
Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation. Mol Cancer Res (2010) 1.07
The consequence of oncomorphic TP53 mutations in ovarian cancer. Int J Mol Sci (2013) 1.07
Ultraslow oligomerization equilibria of p53 and its implications. Proc Natl Acad Sci U S A (2009) 1.07
Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway. J Cell Physiol (2010) 1.05
Interaction of the p53 DNA-binding domain with its n-terminal extension modulates the stability of the p53 tetramer. J Mol Biol (2011) 1.04
Translational approaches targeting the p53 pathway for anti-cancer therapy. Br J Pharmacol (2012) 1.04
Curcumin inhibits protein phosphatases 2A and 5, leading to activation of mitogen-activated protein kinases and death in tumor cells. Carcinogenesis (2012) 1.03
Stabilizing proteins from sequence statistics: the interplay of conservation and correlation in triosephosphate isomerase stability. J Mol Biol (2012) 1.03
Bioinformatics and variability in drug response: a protein structural perspective. J R Soc Interface (2012) 1.01
p53 binding to nucleosomal DNA depends on the rotational positioning of DNA response element. J Biol Chem (2009) 0.99
Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases. Chem Rev (2014) 0.98
Molecular dynamics simulations of p53 DNA-binding domain. J Phys Chem B (2007) 0.94
Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain. Biochemistry (2011) 0.92
Small molecule compounds targeting the p53 pathway: are we finally making progress? Apoptosis (2014) 0.90
Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding. Protein Sci (2010) 0.90
Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. Clin Cancer Res (2014) 0.88
Identifying druggable targets by protein microenvironments matching: application to transcription factors. CPT Pharmacometrics Syst Pharmacol (2014) 0.87
Stability of the core domain of p53: insights from computer simulations. BMC Bioinformatics (2008) 0.87
Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer. Drug Discov Today (2015) 0.86
Stability of p53 homologs. PLoS One (2012) 0.86
Molecular mechanisms of functional rescue mediated by P53 tumor suppressor mutations. Biophys Chem (2009) 0.86
DIVE: a data intensive visualization engine. Bioinformatics (2013) 0.85
Active Constituents from Liriope platyphylla Root against Cancer Growth In Vitro. Evid Based Complement Alternat Med (2013) 0.84
Mapping the structural and dynamical features of multiple p53 DNA binding domains: insights into loop 1 intrinsic dynamics. PLoS One (2013) 0.84
Stabilising the DNA-binding domain of p53 by rational design of its hydrophobic core. Protein Eng Des Sel (2009) 0.84
Tracing the protectors path from the germ line to the genome. Proc Natl Acad Sci U S A (2010) 0.84
Structural studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor mutations via alternative protein-DNA interactions. Nucleic Acids Res (2013) 0.84
Aryl hydrocarbon receptor nuclear translocator (ARNT) isoforms control lymphoid cancer cell proliferation through differentially regulating tumor suppressor p53 activity. Oncotarget (2016) 0.84
Cancer: Mutant p53 and chromatin regulation. Nature (2015) 0.83
Resuscitating wild-type p53 expression by disrupting ceramide glycosylation: a novel approach to target mutant p53 tumors. Cancer Res (2011) 0.83
Effects of stability on the biological function of p53. J Biol Chem (2009) 0.82
Evaluating Drosophila p53 as a model system for studying cancer mutations. J Biol Chem (2012) 0.82
Ensemble-based computational approach discriminates functional activity of p53 cancer and rescue mutants. PLoS Comput Biol (2011) 0.82
Protein evolution via amino acid and codon elimination. PLoS One (2010) 0.81
Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Oncotarget (2016) 0.81
Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination. Mol Cancer Res (2016) 0.81
Impact of low-frequency hotspot mutation R282Q on the structure of p53 DNA-binding domain as revealed by crystallography at 1.54 angstroms resolution. Acta Crystallogr D Biol Crystallogr (2008) 0.80
FUSE Binding Protein 1 Facilitates Persistent Hepatitis C Virus Replication in Hepatoma Cells by Regulating Tumor Suppressor p53. J Virol (2015) 0.80
Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53. Structure (2015) 0.80
Rescue of deleterious mutations by the compensatory Y30F mutation in ketosteroid isomerase. Mol Cells (2013) 0.80
The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget (2016) 0.79
Virilizing adrenocortical carcinoma in a child with Turner syndrome and somatic TP53 gene mutation. Eur J Pediatr (2009) 0.79
A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation. J Biol Chem (2013) 0.79
Structural basis for mutation-induced destabilization of profilin 1 in ALS. Proc Natl Acad Sci U S A (2015) 0.79
A spiroligomer α-helix mimic that binds HDM2, penetrates human cells and stabilizes HDM2 in cell culture. PLoS One (2012) 0.78
How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures. ChemMedChem (2015) 0.78
Discovery of Azurin-Like Anticancer Bacteriocins from Human Gut Microbiome through Homology Modeling and Molecular Docking against the Tumor Suppressor p53. Biomed Res Int (2016) 0.78
Gain of function of mutant p53: R282W on the peak? Oncogenesis (2016) 0.77
Core domain mutant Y220C of p53 protein has a key role in copper homeostasis in case of free fatty acids overload. Biometals (2015) 0.77
QM-MM simulations on p53-DNA complex: a study of hot spot and rescue mutants. J Mol Model (2013) 0.77
Experimental and Theoretical Evaluation of the Ethynyl Moiety as a Halogen Bioisostere. ACS Chem Biol (2015) 0.76
2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells. Proc Natl Acad Sci U S A (2016) 0.76
Structure-based predictions broadly link transcription factor mutations to gene expression changes in cancers. Nucleic Acids Res (2014) 0.76
The gain of function of p53 mutant p53S in promoting tumorigenesis by cross-talking with H-RasV12. Int J Biol Sci (2012) 0.76
Wrapping effects within a proposed function-rescue strategy for the Y220C oncogenic mutation of protein p53. PLoS One (2013) 0.76
A comparison of multiscale methods for the analysis of molecular dynamics simulations. J Phys Chem B (2012) 0.76
Simul-seq: combined DNA and RNA sequencing for whole-genome and transcriptome profiling. Nat Methods (2016) 0.75
Hydrogen Bond Dynamic Propensity Studies for Protein Binding and Drug Design. PLoS One (2016) 0.75
Switch region for pathogenic structural change in conformational disease and its prediction. PLoS One (2010) 0.75
The "Jekyll and Hyde" Actions of Nucleic Acids on the Prion-like Aggregation of Proteins. J Biol Chem (2016) 0.75
The novel p53 isoform "delta p53" is a misfolded protein and does not bind the p21 promoter site. Protein Sci (2008) 0.75
Integrating in silico prediction methods, molecular docking, and molecular dynamics simulation to predict the impact of ALK missense mutations in structural perspective. Biomed Res Int (2014) 0.75
Harnessing Fluorine-Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs. ACS Chem Biol (2016) 0.75
An in silico algorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein. Protein Eng Des Sel (2016) 0.75
Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma. Exp Hematol Oncol (2015) 0.75
Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue. Acta Crystallogr D Biol Crystallogr (2013) 0.75
Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model. J Biomed Sci (2016) 0.75
Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. Mod Pathol (2017) 0.75
Reviving the guardian of the genome: Small molecule activators of p53. Pharmacol Ther (2017) 0.75
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
Surfing the p53 network. Nature (2000) 35.36
Raster3D: photorealistic molecular graphics. Methods Enzymol (1997) 27.30
Prediction of deleterious human alleles. Hum Mol Genet (2001) 21.00
Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science (1996) 19.48
Live or let die: the cell's response to p53. Nat Rev Cancer (2002) 15.06
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (1994) 13.51
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
Detection, delineation, measurement and display of cavities in macromolecular structures. Acta Crystallogr D Biol Crystallogr (1994) 7.53
Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science (1995) 3.69
Structural basis of DNA recognition by p53 tetramers. Mol Cell (2006) 3.29
Rescuing the function of mutant p53. Nat Rev Cancer (2001) 2.95
The UMD-p53 database: new mutations and analysis tools. Hum Mutat (2003) 2.89
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nat Struct Biol (1995) 2.75
Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene (2000) 2.65
Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. Genes Dev (2002) 2.26
The response of T4 lysozyme to large-to-small substitutions within the core and its relation to the hydrophobic effect. Protein Sci (1998) 2.02
Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J Biol Chem (2003) 1.94
Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor. EMBO J (2002) 1.92
p53 contains large unstructured regions in its native state. J Mol Biol (2002) 1.75
Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc Natl Acad Sci U S A (1999) 1.73
Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J Biol Chem (2005) 1.67
Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci U S A (2003) 1.63
Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J (1998) 1.62
Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains. J Biol Chem (2006) 1.61
Stability and folding of the tumour suppressor protein p16. J Mol Biol (1999) 1.61
Structure of the p53 core domain dimer bound to DNA. J Biol Chem (2006) 1.60
Structural and energetic responses to cavity-creating mutations in hydrophobic cores: observation of a buried water molecule and the hydrophilic nature of such hydrophobic cavities. Biochemistry (1996) 1.60
Core domain interactions in full-length p53 in solution. Proc Natl Acad Sci U S A (2006) 1.59
Solution structure of p53 core domain: structural basis for its instability. Proc Natl Acad Sci U S A (2006) 1.53
A temperature-sensitive mutant of human p53. EMBO J (1994) 1.51
Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J (2000) 1.38
Binding of Rad51 and other peptide sequences to a promiscuous, highly electrostatic binding site in p53. J Biol Chem (2004) 1.31
Crystal structural analysis of mutations in the hydrophobic cores of barnase. J Mol Biol (1993) 1.30
Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene (1998) 1.29
Mutational analysis of the p53 core domain L1 loop. J Biol Chem (2006) 1.25
The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes. Mol Cell Biol (2006) 1.24
Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ (2006) 1.23
Recognition of DNA by p53 core domain and location of intermolecular contacts of cooperative binding. J Mol Biol (2002) 1.22
Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem (2003) 1.16
Small molecules that reactivate mutant p53. Eur J Cancer (2003) 1.13
NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA. J Biol Chem (2001) 1.12
Structural differences in the DNA binding domains of human p53 and its C. elegans ortholog Cep-1. Structure (2004) 1.06
Effects of oncogenic mutations and DNA response elements on the binding of p53 to p53-binding protein 2 (53BP2). J Biol Chem (2006) 1.04
Comparison of the human and worm p53 structures suggests a way for enhancing stability. Biochemistry (2006) 0.88
Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer (2009) 5.12
The complete folding pathway of a protein from nanoseconds to microseconds. Nature (2003) 3.61
The crystal structure of human CD1d with and without alpha-galactosylceramide. Nat Immunol (2005) 3.53
Structural biology of the tumor suppressor p53. Annu Rev Biochem (2008) 3.36
A transient and low-populated protein-folding intermediate at atomic resolution. Science (2010) 3.08
Is there a unifying mechanism for protein folding? Trends Biochem Sci (2003) 2.63
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci U S A (2008) 2.30
Cooperative binding of tetrameric p53 to DNA. J Mol Biol (2004) 2.26
Unifying features in protein-folding mechanisms. Proc Natl Acad Sci U S A (2003) 2.24
Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain. Proc Natl Acad Sci U S A (2008) 2.14
Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex. Proc Natl Acad Sci U S A (2007) 2.09
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell (2009) 2.09
Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol (2002) 2.03
Comparative binding of p53 to its promoter and DNA recognition elements. J Mol Biol (2005) 1.96
Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J Biol Chem (2003) 1.94
Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53. Proc Natl Acad Sci U S A (2007) 1.86
General structural motifs of amyloid protofilaments. Proc Natl Acad Sci U S A (2006) 1.72
Tumor suppressor p53 slides on DNA with low friction and high stability. Biophys J (2008) 1.70
Testing protein-folding simulations by experiment: B domain of protein A. Proc Natl Acad Sci U S A (2004) 1.70
Kinetic instability of p53 core domain mutants: implications for rescue by small molecules. J Biol Chem (2003) 1.68
Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J Biol Chem (2005) 1.67
The central region of HDM2 provides a second binding site for p53. Proc Natl Acad Sci U S A (2006) 1.67
Direct observation of barrier-limited folding of BBL by single-molecule fluorescence resonance energy transfer. Proc Natl Acad Sci U S A (2009) 1.65
The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol (2010) 1.64
The crystal structure of human CD1b with a bound bacterial glycolipid. J Immunol (2004) 1.64
Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains. J Biol Chem (2006) 1.61
Core domain interactions in full-length p53 in solution. Proc Natl Acad Sci U S A (2006) 1.59
A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci U S A (2002) 1.58
Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA. Nucleic Acids Res (2008) 1.58
Solution structure of p53 core domain: structural basis for its instability. Proc Natl Acad Sci U S A (2006) 1.53
Phi-analysis at the experimental limits: mechanism of beta-hairpin formation. J Mol Biol (2006) 1.53
Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor. Proc Natl Acad Sci U S A (2005) 1.52
Ultra-fast barrier-limited folding in the peripheral subunit-binding domain family. J Mol Biol (2005) 1.52
The denatured state of Engrailed Homeodomain under denaturing and native conditions. J Mol Biol (2003) 1.51
Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene (2002) 1.51
Halogen-enriched fragment libraries as leads for drug rescue of mutant p53. J Am Chem Soc (2012) 1.50
Structural evolution of p53, p63, and p73: implication for heterotetramer formation. Proc Natl Acad Sci U S A (2009) 1.46
A single-molecule characterization of p53 search on DNA. Proc Natl Acad Sci U S A (2010) 1.43
Sequential unfolding of ankyrin repeats in tumor suppressor p16. Structure (2003) 1.43
Direct observation of ultrafast folding and denatured state dynamics in single protein molecules. Proc Natl Acad Sci U S A (2009) 1.39
14-3-3 activation of DNA binding of p53 by enhancing its association into tetramers. Nucleic Acids Res (2008) 1.36
Distinguishing between cooperative and unimodal downhill protein folding. Proc Natl Acad Sci U S A (2007) 1.35
Rapid amyloid fiber formation from the fast-folding WW domain FBP28. Proc Natl Acad Sci U S A (2003) 1.33
Binding of Rad51 and other peptide sequences to a promiscuous, highly electrostatic binding site in p53. J Biol Chem (2004) 1.31
Early events in protein folding. Curr Opin Struct Biol (2003) 1.28
Correlation of levels of folded recombinant p53 in escherichia coli with thermodynamic stability in vitro. J Mol Biol (2007) 1.27
Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. Chem Biol (2010) 1.27
Simulation and experiment conspire to reveal cryptic intermediates and a slide from the nucleation-condensation to framework mechanism of folding. J Mol Biol (2005) 1.27
Modulation of the oligomerization state of p53 by differential binding of proteins of the S100 family to p53 monomers and tetramers. J Biol Chem (2009) 1.25
Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res (2013) 1.24
One-state downhill versus conventional protein folding. J Mol Biol (2004) 1.24
The helix-turn-helix motif as an ultrafast independently folding domain: the pathway of folding of Engrailed homeodomain. Proc Natl Acad Sci U S A (2007) 1.23
Comparative biophysical characterization of p53 with the pro-apoptotic BAK and the anti-apoptotic BCL-xL. J Biol Chem (2007) 1.23
Recognition of DNA by p53 core domain and location of intermolecular contacts of cooperative binding. J Mol Biol (2002) 1.22
Regulation of DNA binding of p53 by its C-terminal domain. J Mol Biol (2004) 1.22
Demonstration of a low-energy on-pathway intermediate in a fast-folding protein by kinetics, protein engineering, and simulation. Proc Natl Acad Sci U S A (2004) 1.21
Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition. Proc Natl Acad Sci U S A (2012) 1.21
Single-Molecule characterization of oligomerization kinetics and equilibria of the tumor suppressor p53. Nucleic Acids Res (2010) 1.20
Carboxyl pK(a) values and acid denaturation of BBL. J Mol Biol (2010) 1.20
Binding of natively unfolded HIF-1alpha ODD domain to p53. Mol Cell (2005) 1.18
Two sequence motifs from HIF-1alpha bind to the DNA-binding site of p53. Proc Natl Acad Sci U S A (2002) 1.18
Physical and functional interactions between human mitochondrial single-stranded DNA-binding protein and tumour suppressor p53. Nucleic Acids Res (2008) 1.18
CRINEPT-TROSY NMR reveals p53 core domain bound in an unfolded form to the chaperone Hsp90. Proc Natl Acad Sci U S A (2002) 1.17
Acetylation of lysine 120 of p53 endows DNA-binding specificity at effective physiological salt concentration. Proc Natl Acad Sci U S A (2011) 1.16
Multiple conformations of full-length p53 detected with single-molecule fluorescence resonance energy transfer. Proc Natl Acad Sci U S A (2009) 1.13
Biophysical characterizations of human mitochondrial transcription factor A and its binding to tumor suppressor p53. Nucleic Acids Res (2009) 1.13
Conformational entropy of alanine versus glycine in protein denatured states. Proc Natl Acad Sci U S A (2007) 1.13
Sequence-dependent sliding kinetics of p53. Proc Natl Acad Sci U S A (2012) 1.13
The structure of the major transition state for folding of an FF domain from experiment and simulation. J Mol Biol (2005) 1.10
A structural double-mutant cycle: estimating the strength of a buried salt bridge in barnase. Acta Crystallogr D Biol Crystallogr (2002) 1.10
The kinetic pathway of folding of barnase. J Mol Biol (2003) 1.09
Electron microscopy studies on the quaternary structure of p53 reveal different binding modes for p53 tetramers in complex with DNA. Proc Natl Acad Sci U S A (2010) 1.08
Structural biology of the tumor suppressor p53 and cancer-associated mutants. Adv Cancer Res (2007) 1.07
Ultraslow oligomerization equilibria of p53 and its implications. Proc Natl Acad Sci U S A (2009) 1.07
Structural biology: analysis of 'downhill' protein folding. Nature (2007) 1.07
Modulation of binding of DNA to the C-terminal domain of p53 by acetylation. Structure (2005) 1.06
Solution structure of the C4 zinc finger domain of HDM2. Protein Sci (2005) 1.06
Simulation and experiment at high temperatures: ultrafast folding of a thermophilic protein by nucleation-condensation. J Mol Biol (2005) 1.06
Phi-analysis of the folding of the B domain of protein A using multiple optical probes. J Mol Biol (2006) 1.06
First-order rate-determining aggregation mechanism of p53 and its implications. Proc Natl Acad Sci U S A (2012) 1.06
Determination of the folding transition states of barnase by using PhiI-value-restrained simulations validated by double mutant PhiIJ-values. Proc Natl Acad Sci U S A (2005) 1.05
Mimicking natural evolution in vitro: an N-acetylneuraminate lyase mutant with an increased dihydrodipicolinate synthase activity. Proc Natl Acad Sci U S A (2003) 1.05
The role of the turn in beta-hairpin formation during WW domain folding. Protein Sci (2007) 1.05
Interaction of the p53 DNA-binding domain with its n-terminal extension modulates the stability of the p53 tetramer. J Mol Biol (2011) 1.04
Effects of oncogenic mutations and DNA response elements on the binding of p53 to p53-binding protein 2 (53BP2). J Biol Chem (2006) 1.04
Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad Sci U S A (2003) 1.04
Interaction between the transactivation domain of p53 and PC4 exemplifies acidic activation domains as single-stranded DNA mimics. J Biol Chem (2009) 1.04
Members of the S100 family bind p53 in two distinct ways. Protein Sci (2008) 1.03
Downhill versus barrier-limited folding of BBL 1: energetic and structural perturbation effects upon protonation of a histidine of unusually low pKa. J Mol Biol (2008) 1.03
Don't waste good methods on bad buffers and ambiguous data. Proc Natl Acad Sci U S A (2013) 1.03
Posttranslational modifications affect the interaction of S100 proteins with tumor suppressor p53. J Mol Biol (2009) 1.02
Kinetics of chain motions within a protein-folding intermediate. Proc Natl Acad Sci U S A (2010) 1.01
Analogues with fluorescent leaving groups for screening and selection of enzymes that efficiently hydrolyze organophosphorus nerve agents. J Med Chem (2006) 0.99
Intrinsically disordered p53 and its complexes populate compact conformations in the gas phase. Angew Chem Int Ed Engl (2012) 0.98
Chemical physics of protein folding. Proc Natl Acad Sci U S A (2012) 0.98